Indivior Pharmaceuticals Inc
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a INDV research report →
Companywww.indivior.com
Indivior Pharmaceuticals Inc is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, and Subutex Tablet. It operates through the following geographical segments: United States, Rest of World, and United Kingdom.
- CEO
- Joseph J. Ciaffoni
- IPO
- 2014
- Employees
- 1,030
- HQ
- North Chesterfield, VA, US
Price Chart
Valuation
- Market Cap
- $4.69B
- P/E
- 18.77
- P/S
- 3.63
- P/B
- -32.72
- EV/EBITDA
- 11.12
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 83.11%
- Op Margin
- 33.31%
- Net Margin
- 19.44%
- ROE
- -142.01%
- ROIC
- 85.68%
Growth & Income
- Revenue
- $1.24B · 4.29%
- Net Income
- $210.00M · 10400.00%
- EPS
- $1.68 · 11025.83%
- Op Income
- $265.00M
- FCF YoY
- -1428.57%
Performance & Tape
- 52W High
- $41.00
- 52W Low
- $11.08
- 50D MA
- $33.38
- 200D MA
- $30.57
- Beta
- 1.20
- Avg Volume
- 2.65M
Get TickerSpark's AI analysis on INDV
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 13, 26 | Thompson Juliet | other | 6,518 |
| May 12, 26 | Thompson Juliet | other | 1,117 |
| May 13, 26 | Humphreys Keith | other | 6,518 |
| May 13, 26 | Kingsley Stuart A | other | 6,518 |
| May 13, 26 | NINIVAGGI DANIEL A | other | 6,518 |
| May 13, 26 | Ryan Barbara | other | 6,518 |
| May 13, 26 | Stejbach Mark | other | 6,518 |
| May 13, 26 | Wheadon David E. | other | 10,430 |
| Mar 14, 26 | Preblick Ryan | other | 6,302 |
| Mar 14, 26 | Preblick Ryan | other | 2,843 |
Our INDV Coverage
We haven't published any research on INDV yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate INDV Report →